Sandoz Ups Biosimilar Game With Alteogen Subcutaneous Tech Deal
Alteogen Comments Suggests Deal Worth Up To $145m
Executive Summary
Sandoz is eyeing development of up to three subcutaneous formulation biosimilars, which offer greater benefits to both patients and healthcare providers, via a technology agreement with Korean firm Alteogen.
You may also be interested in...
The Hunt For Big Fish: How KDDF Is Helping Create Korean Deals
Korea Drug Development Fund CEO H. Samuel Muk talks to Scrip how the government agency has evolved to support the Korean biopharma industry’s R&D and business development activities, as well as what key new projects are underway.
Deal Watch: AbbVie Leads J.P. Morgan Deal Rush, But BI, Genentech And Lilly Also Big Players
As the usual flurry of deals coincides with the J.P. Morgan Healthcare Conference, AbbVie signed an mRNA pact with Anima and a cancer research tie-up with Immunome.
Alteogen Eyes First-Mover Advantage For Eylea Biosimilar
Korea’s Alteogen believes that formulation patents granted in the EU, US and Japan as well as a pending process patent may offer it a first-mover advantage on biosimilar aflibercept. The firm has just completed a Phase I trial for its proposed rival to Eylea.